Hussman Strategic Advisors Inc. Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Hussman Strategic Advisors Inc. decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 60.0% during the fourth quarter, Holdings Channel reports. The fund owned 42,000 shares of the biopharmaceutical company’s stock after selling 63,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in TG Therapeutics were worth $1,264,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in TGTX. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares during the period. Private Advisor Group LLC boosted its position in shares of TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 542 shares during the last quarter. Brookstone Capital Management lifted its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 624 shares during the last quarter. Daymark Wealth Partners LLC grew its position in TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock worth $1,249,000 after acquiring an additional 689 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its holdings in shares of TG Therapeutics by 1.9% in the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock worth $1,317,000 after purchasing an additional 837 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

TGTX has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. TD Cowen began coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Finally, The Goldman Sachs Group increased their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $31.01 on Thursday. The company’s 50 day moving average is $31.09 and its 200 day moving average is $27.61. The company has a market cap of $4.83 billion, a PE ratio of -310.07 and a beta of 2.26. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.